BioLife Solutions, Inc.

NASDAQ:BLFS

Medical - Instruments & Supplies

Healthcare
$38.61 +1.56%

+$0.40 today

Market cap
$1.89B
Beta
1.97
P/E (TTM)
-119.9
EPS (TTM)
-$0.22
52W Low $17.86High $29.62

Volume 4.39M

Average 0.52M

BLFS Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

BioLife Solutions, Inc.NASDAQ: BLFS

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses grows, but more slowly than its trailing trend

Q1 FY2026 operating expenses of $17.38M rose 2.2% year over year, behind the +94.5% change in trailing-twelve-month operating expenses. Sequentially, it rose 153.5% from the prior quarter. Over 3 fiscal years it compounded at +12.0% a year.

Context

  • Operating expenses amounted to 77.2% of revenue in FY2025, up 3.3 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +2.2% toward the trailing-twelve-month pace of +94.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$17.38M+153.5% QoQ
Last fiscal yearDec 2025
$74.25M+22.1% YoY
LTMMar 2026
$74.63M+94.5% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.2%——
1 year+22.1%——
3-year CAGR+12.0%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
74.25M USD
Year-over-year change
+22.1%
4-year CAGR
+0.3%

Operating Expenses vs competitors

How BLFS compares with its peers on the latest reported figures

  • BLFS's LTM Mar 2026 operating expenses of $74.63M is the lowest of the 11 companies compared; the peer median is $274.72M.
  • Its year-over-year change of +94.5% is the highest of 11, against a peer median of +10.2%.
  • Operating expenses amounts to 74.8% of revenue for BLFS, versus a peer median of 75.2%.
BLFS Competitors Peer median
Operating Expenses for BLFS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$690.48M +6.8%+7.8%102.4%
AZTAAzenta, Inc.LTM Sep 2026$447.31M +59.0%+12.5%71.9%
NEOGNeogen CorporationLTM Aug 2026$426.36M +16.9%+5.3%48.2%
ATRCAtriCure, Inc.LTM Jun 2026$419.96M +3.0%+11.6%73.7%
PHRPhreesia, Inc.LTM Apr 2026$322.49M -4.5%-1.5%65.1%
STAASTAAR Surgical CompanyLTM Apr 2026$226.94M -17.3%+8.3%78.2%
ESTAEstablishment Labs Holdings Inc.LTM Sep 2026$202.65M +9.5%+8.2%76.8%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$184.42M +91.1%—220.3%
HROWHarrow Health, Inc.LTM Mar 2026$170.99M +10.9%+39.3%63.6%
PLSEPulse Biosciences, Inc.LTM Jun 2026$82.79M +15.0%+17.4%6986.2%
BLFSBioLife Solutions, Inc.LTM Mar 2026$74.63M +94.5%+12.0%74.8%
Peer median (excluding BLFS) $274.72M+10.2%+8.3%75.2%

Competitors are the stored peer set for BLFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue119.16M76.24M75.86M82.25M96.21M
Cost of Revenue90.31M29.33M96.52M28.58M34.1M
Gross Profit28.85M46.91M46.75M53.67M62.12M
Gross Margin24.2%61.5%61.6%65.3%64.6%
Research & Development11.82M14.8M18.8M7.91M7.57M
Selling, General & Admin48.09M44.93M55.97M50.15M55.37M
Operating Expenses73.34M52.83M117.58M60.8M74.25M
Depreciation & Amortization12.87M19.96M12.3M8.66M4.69M
EBITDA(16.65M)(124.18M)(45.24M)1.53M3.61M
EBITDA Margin-14.0%-162.9%-59.6%1.9%3.7%
Operating Income(35.16M)(5.92M)(23.44M)(7.13M)(1.08M)
Operating Margin-29.5%-7.8%-30.9%-8.7%-1.1%
Interest Income00000
Interest Expense485K687K1.81M719K2.71M
Other Income / Expenses6.13M1.08M4.97M(4.3M)(11M)
Income Before Tax(29.03M)(4.85M)(18.47M)(11.43M)(12.08M)
Pre-Tax Margin-24.4%-6.4%-24.4%-13.9%-12.6%
Income Tax Expense(20.12M)(5.24M)24K(38K)49K
Net Income(8.91M)(139.81M)(66.43M)(20.18M)(12.13M)
Net Margin-7.5%-183.4%-87.6%-24.5%-12.6%
EPS (Basic)(0.23)(3.29)(1.52)(0.44)(0.25)
EPS (Diluted)(0.23)(3.29)(1.52)(0.44)(0.25)
Weighted Avg Shares38.5M42.48M43.72M46.07M47.75M
Weighted Avg Shares (Diluted)38.5M42.48M43.72M46.07M48.65M

BioLife Solutions, Inc.

NASDAQ:BLFS

Intrinsic Alpha fair value

Locked

Current Price

$38.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.